Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 7.9% – Time to Buy?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s stock price was up 7.9% on Monday . The company traded as high as $101.69 and last traded at $101.52. Approximately 26,123 shares traded hands during trading, a decline of 79% from the average daily volume of 122,218 shares. The stock had previously closed at $94.09.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Raymond James Financial upgraded shares of Palvella Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $92.00 to $143.00 in a research note on Wednesday, November 19th. Cantor Fitzgerald raised their price target on Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Chardan Capital reaffirmed a “buy” rating and set a $110.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, November 13th. Canaccord Genuity Group increased their price objective on Palvella Therapeutics from $90.00 to $148.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, Oppenheimer reissued an “outperform” rating on shares of Palvella Therapeutics in a report on Tuesday, November 11th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Palvella Therapeutics presently has a consensus rating of “Buy” and an average target price of $117.33.

Palvella Therapeutics Stock Performance

The firm has a fifty day moving average price of $73.68 and a 200 day moving average price of $48.31. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -37.90 and a beta of -0.05.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). Research analysts predict that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $86.23, for a total transaction of $370,961.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PVLA. Archer Investment Corp purchased a new stake in Palvella Therapeutics in the 3rd quarter valued at approximately $28,000. Russell Investments Group Ltd. purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Palvella Therapeutics during the second quarter valued at $37,000. JPMorgan Chase & Co. increased its position in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Palvella Therapeutics in the 2nd quarter valued at about $85,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.